Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer

30 Oct 2020

Abstract excerpt

Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to systemic tumor recurrence of metastatic disease. Herein, we conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts. These data demonstrate the induction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Axon Guidance and Neuronal Signaling
Share to Lymphatic System and Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33128042
DOI: 10.1038/s41388-020-01530-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancerPMID 33128042Read ↗

Neuropilin-1 Knockout and Rescue Confirms Its Role to Promote Metastasis in MDA-MB-231 Breast Cancer CellsSemantic proximity Read ↗

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired ResistanceSemantic proximity Read ↗

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancerSemantic proximity Read ↗

NR2F1 Is a Barrier to Dissemination of Early-Stage Breast Cancer CellsSemantic proximity Read ↗

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsSemantic proximity Read ↗

Mesenchymal change and drug resistance in neuroblastoma.Semantic proximity Read ↗

FGFR1 is a potential therapeutic target in neuroblastomaSemantic proximity Read ↗

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.Semantic proximity Read ↗

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>Semantic proximity Read ↗

Neuropilins Controlling Cancer Therapy ResponsivenessSemantic proximity Read ↗

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axisSemantic proximity Read ↗

RELN signaling modulates glioblastoma growth and substrate‐dependent migrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.